New cancer drug enters first human testing phase
NCT ID NCT05114668
Summary
This early-stage study tested the safety of a new oral drug called EVT801 in 32 adults with advanced solid tumors that hadn't responded to standard treatments. Researchers aimed to find the highest safe dose patients could tolerate daily and gather initial information about how the drug behaves in the body. The study also explored whether the drug showed any early signs of affecting tumors in specific cancer types.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.